Bolder BioPath

About Us
Services
Publications
Request a Quote
Contact

Rheumatoid Arthritis
Osteoarthritis
Inflammatory Bowel Disease
Lupus
General Inflammation
Pain
Cancer
Toxicology and Pharmacokinetic Studies
Ex Vivo Services
Pathology
Anemia
Model Development

Rheumatoid Arthritis
Osteoarthritis
Inflammatory Bowel Disease
Lupus
General Inflammation
Pain
Cancer
Toxicology and Pharmacokinetic Studies
Ex Vivo Services
Pathology
Anemia
Model Development

Models We Conduct

Histotype

Lung
Colon
Breast
Prostate
Ovarian
Renal
CNS
Pancreatic
Leukemia
Other

Renal

Tumor Cell Lines (Click to Enlarge Image):

: rxf631

: sn12c

: sn12k1

Tell Us About Your Project! Get a Quote »

Contact Us

CAPTCHA
Name
This field is for validation purposes and should be left unchanged.

Recent Posts

A Novel ROR-Gamma Inhibitor (VPR-254) Attenuates Key Parameters of Innate Immune Colitis in Mice

05-02-17

Come hear Leo Fitzpatrick discuss the paper, A Novel ROR-Gamma Inhibitor (VPR-254) Attenuates Key Parameters of Innate Immune Colitis in Mice, this Saturday May 6, from 10:30am-10:45am in Room S102d at McCormick Place, California NorthState University College of Pharmacy. Authors: Leo Fitzpatrick, Robert O’Connell, George Talbott, Phillip Bendele, Gordon Alton, Jim Zapf

AAALAC Accreditation

03-14-17

Bolder BioPATH now has FULL accreditation through AAALAC International, effective as of March 9, 2017.
OARSI 2017 World Congress on Osteoarthritis

01-24-17

Come meet Bolder BioPATH at the OARSI 2017 World Congress on Osteoarthritis in Las Vegas from April 27 to 30! We’ll be set up in booth #8.

Digestive Disease Week Conference, May 6-9

12-22-16

Come meet Bolder BioPATH at the DDW Conference in Chicago from May 6 to 9! We’ll be set up in booth #1712.
Important Things to Know About Intra-Articular Testing of Drugs in Animals – ACT’s 37th Annual Meeting

08-25-16

Important Things to Know About Intra-Articular Testing of Drugs in Animals Alison M. Bendele DVM, PhD, DACVP Bolder BioPATH, Inc, Boulder, CO Monday Nov. 7th – Symposium 7 , 3:50 PM–4.20 PM Intra-articular (IA) administration of drugs offers an opportunity to directly target joints (primarily osteoarthritic) for anabolic, antidegenerative, analgesic, lubricant, anti-inflammatory and other potential […]

Now offering FACS analysis through Clinimmune Labs.

08-23-16

Bolder BioPATH has started offering FACS analysis on some of our models with help from the folks at Clinimmune Labs in Denver.
19th IRA International Conference – 2016

07-22-16

Come by Bolder BioPATH’s booth at the 19th IRA International Conference in San Diego. We hope to see you there!

Atlas-Backed Nimbus Delivers Its Apollo Mission: A $1.2B Gilead Partnership

04-26-16

Today Gilead announced the acquisition of Nimbus’ lead program targeting NASH and related metabolic disorders for $400M upfront and up to another $800M in development and regulatory milestones (here).

Website designed by Studio98

In Vivo efficacy models
Ex Vivo Services
Pathology
Terms of Service
Privacy Policy

©2015 Bolder BioPATH, INC. All rights reserved.Privacy Policy